NCT00931320

Completed

Investigation Into the RAtio of LDL-CHolestEroL to HDL-Chole...

AstraZeneca Source

Compare

Other study identifiers

Sponsor study identifier

NIS-CKR-DUM-2009/3

Study Type

observational

Estimated enrollment

3,000

Locations

0 countries

Sites

N/A

Timeline

Study Start

July 2009

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

Not reported

Date not reported

Study Completion

September 2009

Actual (reported)

Brief Summary

An observational, non-interventional, multi-centre study to provide further information on the ratio of LDL-C to HDL-C improvement after statin treatment in Korean patients group.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Estimated enrollment: 3,000 participants
Study completion date: September 2009
Actual (reported)
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
June 30, 2009
Actual (reported)
Study Start
July 2009
Date type not reported
This date has not been verified as actual or estimated.
First Posted
July 2, 2009
Actual (reported)
Study Completion
September 2009
Actual (reported)

Last Updated: October 27, 2009
Status Verified: October 2009
Last Update Submitted: October 23, 2009

Conditions

Dyslipidemias

Keywords

Ratio improvementLDL-CHDL-CRatio of Low Density Lipoprotein Cholesterol to High Density Lipoprotein Cholesterol ImprovementHigh Density Lipoprotein Cholesterol

Outcome Measures

Primary Outcomes (1)

Evaluate current LDL/HDL ratio in Korean patients (between baseline & after treatment)
After Treatment : at least 4 weeks before statin taking /Baseline : no limitation.

Secondary Outcomes (1)

Evaluate difference of LDL/HDL ratio among different statins & dosages (between baseline & after treatment)
After Treatment : at least 4 weeks before statin taking / Baseline : no limitation.

Study Arms (1)

3000 patients

Who have at least made 1 visit to the outpatient clinic within previous 6 months .

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Who have at least made 1 visit to the outpatient clinic within previous 6 months .

You may qualify if:

Subjects who are taking lipid-lowering medication after diagnosed as dyslipidaemia

Sponsors & Collaborators

AstraZeneca
Industrylead

MeSH Terms

Conditions

Dyslipidemias

Condition Hierarchy (Ancestors)

Lipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

Hyunah Caroline Choi
AstraZeneca Korea
STUDY DIRECTOR

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: RETROSPECTIVE
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

June 30, 2009

First Posted

July 2, 2009

Study Start

July 2009

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

September 2009

Actual (reported)

NCT00895141

Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL)

Not ApplicableCompleted

NCT01058083

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Phase 2Completed

NCT01010516

Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia

Phase 4Unknown

NCT01164397

Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients

Completed

NCT01025492

Study of Trilipix Effects on Lipids and Arteries

Phase 4Terminated

NCT00977288

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Phase 2Completed

Subjects who have at least made 1 visit to the outpatient clinic within previous 6 months

Subjects who have records of both LDL-C and HDL-C before \& after statin treatment (at least four weeks after statin taking)

You may not qualify if:

Subjects who are unwilling or unable to provide their examination and lab result of medical chart.

Contact the study team to confirm eligibility.

Last Updated

October 27, 2009

Record last verified: 2009-10

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00931320
Data provider: ClinicalTrials.gov
Source updated: 2009-10-27
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:19:50 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (1)

3000 patients

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Source record